Phase 2a Trial Results Show Potential in Treating Cognitive Impairment with Combination Therapy of CST-2032/CST-107.

Published Date: 24 Mar 2024

Patients with mild cognitive impairment or mild dementia from Parkinson's or Alzheimer's disease showed significant improvements in their cognitive function with combination adrenergic activator therapy, according to a phase 2a trial.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Psychedelic Therapy Tied to Reduced Depression, Anxiety.

2.

New drug resistance mechanism in melanoma leptomeningeal disease revealed by study.

3.

Research finds stark disparities in treatment and survival time for people with pancreatic cancer

4.

Tumor characteristics found to differ for melanomas in children, teens and young adults

5.

Relationship-building key to addressing oncologist shortages in rural care


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot